The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1692
December 25, 2023
View Complete Issue         Table of Contents 2019 
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
December 25, 2023 (Issue: 1692)
The FDA has approved the oral GABAA receptor modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression (PPD). Zuranolone is the second drug to be approved for this indication; brexanolone (Zulresso),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
Article code: 1692a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.